Cytokinetics, Inc. (CYTK) Posts Q2 Loss of 23c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Cytokinetics (CYTK) Valuation Remains Attractive Following Q2 Results - Roth
July 31, 2014 2:17 PM EDTRoth Capital reaffirms its Buy rating and $13 price target on Cytokinetics (Nasdaq: CYTK) following the company's Q2 report.
Ahead of the bell, Cytokinetics posted Q2 loss of $0.23 per share with revenue of $7.8 million, versus consensus estimates calling for a loss of $0.32 per share and revs of $7.0 million. Roth was looking for a loss of $0.38 per share and revenue of $4.0 million.
Roth analyst Joseph Pantginis... More
